I agree with Dr. @Geoffrey Y. Ku's comments regarding the Keynote 059, 061, and 062 studies.  However, there are new data presented at the 2020 ESMO meeting. The Keynote 590 is a phase III study enrolled 749 patients with advanced esophageal and GEJ cancer (including esophageal squamous cell ...

Like tweets from some of our politicians, my previous answer has not aged well. I absolutely agree with Dr. @Zhaohui Jin that both Checkmate-649 and KEYNOTE-590 have transformed the treatment of esophagogastric cancer (EGC; both adenocarcinoma and SCC). Broadly speaking, there are now phase III data...

There are no phase III data. The only data so far come from one arm of the KEYNOTE-059 study, where 25 Pts were treated with 5-FU/cisplatin and pembrolizumab (Bang, J Clin Oncol 2017;35:4012 [abstr]). The response rate was 60% and survival data were encouraging. However, in the absence of phase III ...

I will be in the minority, but I am not sure the available data is convincing to use upfront immunotherapy in most patients with esophageal cancer.  1. KN590 really just mimics the results of KN181: there is some benefit for patients with esophageal SCC with CPS>10. The benefit in the over...